BioSpace News Archive

Eiger BioPharmaceuticals, Inc. (Nasdaq: EIGR), focused on the development and commercialization of targeted therapies for serious rare and ultra-rare diseases, today announced end of study post-treatment results of the Phase 2 LIMT HDV Study (Lambda Interferon MonoTherapy in Hepatitis Delta Virus) reported as an oral late breaker presentation at The International Liver Congress™ 2019

QIAGEN N.V. (NYSE: QGEN; Frankfurt Prime Standard: QIA) today announced that its modern gold standard QuantiFERON®-TB test for detection of latent tuberculosis (TB) infections has surpassed 60 million tests administered, having impacted the lives of millions of patients worldwide and supporting the global fight against this public health issue.

Ophthotech Corporation (NASDAQ: OPHT) announced today that the Company has converted its option and entered into an exclusive global license agreement with the University of Pennsylvania

Novanta Inc. (Nasdaq: NOVT) (the “Company”), a trusted technology partner to medical and advanced technology equipment manufacturers, will release its first quarter 2019 results on Tuesday, May 7, 2019.

MiMedx Group, Inc. reinforced its priorities for 2019 as part of its long-range strategic plan to enhance value for all MiMedx stakeholders.

Dr. Richard M. Glickman to retire from executive and board roles and remain an advisor to the Company for one year

Company also awarded “Best Places to Work in Chicago” by Crain’s Chicago Business

National multicenter study of 1,250 patients with chronic kidney disease

Nobilis Health Corp. announced that it has submitted a formal request with the NYSE to extend the Company’s deadline for filing its Q3 2018 financials.

KEYTRUDA Now Approved for First-Line Treatment of Patients with Stage III NSCLC Who Are Not Candidates for Surgical Resection or Definitive Chemoradiation, or Metastatic NSCLC, and Whose Tumors Express PD-L1 (TPS ≥1%), with No EGFR or ALK Genomic Tumor Aberrations